Unknown

Dataset Information

0

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?


ABSTRACT: Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability. In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes. Age did not independently influence survival and ibrutinib tolerance, indicating that not age per se, but age-related conditions, may affect drug management. We confirmed the role of CIRS > 6 as a predictor of a poorer progression- and event-free survival (PFS, EFS). The presence of a severe comorbidity was significantly associated with permanent dose reductions (PDRs), not translating into worse outcomes. As expected, del(17p) and/or TP53mut and previous therapies affected PFS, EFS, and overall survival. No study so far has analyzed the influence of concomitant medications and CYP3A inhibitors with ibrutinib. In our series, these factors had no impact, although CYP3A4 inhibitors use correlated with Cox regression analysis, with an increased risk of PDR. Despite the limitation of its retrospective nature, this large study confirmed the role of ECOG-PS as the most accurate predictor of ibrutinib feasibility and outcomes, and importantly, neutropenia emerged as a relevant tool influencing patients' vulnerability. Although CIRS > 6 retained a significant impact on PFS and EFS, its value should be confirmed by prospective studies.

SUBMITTER: Tedeschi A 

PROVIDER: S-EPMC8714729 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Tedeschi Alessandra A   Frustaci Anna Maria AM   Mauro Francesca Romana FR   Chiarenza Annalisa A   Coscia Marta M   Ciolli Stefania S   Reda Gianluigi G   Laurenti Luca L   Varettoni Marzia M   Murru Roberta R   Baratè Claudia C   Sportoletti Paolo P   Greco Antonino A   Borella Chiara C   Rossi Valentina V   Deodato Marina M   Biagi Annalisa A   Zamprogna Giulia G   Pelle Angelo Curto AC   Lapietra Gianfranco G   Vitale Candida C   Morelli Francesca F   Cassin Ramona R   Fresa Alberto A   Cavalloni Chiara C   Postorino Massimiliano M   Ielo Claudia C   Cairoli Roberto R   Di Raimondo Francesco F   Montillo Marco M   Del Poeta Giovanni G  

Blood advances 20211201 24


Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability. In this series of 712 patients with chronic lymphocytic leukemia (CLL) treat  ...[more]

Similar Datasets

| S-EPMC8772341 | biostudies-literature
| S-EPMC7552812 | biostudies-literature
| S-EPMC4811630 | biostudies-literature
| S-EPMC7275592 | biostudies-literature
| S-EPMC5996546 | biostudies-literature
| S-EPMC5338745 | biostudies-literature
| S-EPMC6906546 | biostudies-literature
| S-EPMC5437732 | biostudies-literature
| S-EPMC8718628 | biostudies-literature